IMF Virtual Myeloma Community Workshop (MCW): Focus on Newly Diagnosed Myeloma (https://www.myeloma.org/videos/imf-virtual-myeloma-community-workshop-mcw)
The IMF Virtual Myeloma Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. A member of the IMF Nurse Leadership Board will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.
Welcome and Announcements
Robin Tuohy
Workshop Moderator
IMF Senior Vice President, Patient Support
IMF Strategic Plan
Myeloma 101: What You Need to Know
Joseph Mikhael, MD, Med, FRCPC, FACP
IMF Chief Medical Officer
(TGen, City of Hope—Phoenix, AZ)
Management For Newly Diagnosed, NOT Going to Transplant
Marc Braunstein, MD, PhD, FACP
Fellowship Program Director
(NYU Grossman Long Island School of Medicine—New York, NY)
Myeloma Management for People Newly Diagnosed: Transplant Eligibility, Logistics & Planning
Noopur Raje, MD
Director, Center for Multiple Myeloma
(Massachusetts General Hospital—Boston, MA)
Living Your Best Myeloma Life: Side Effect Management and Patient Empowerment
Mary Steinbach, DNP, APRN
IMF Nurse Leadership Board Member
(Huntsman Cancer Institute, University of Utah—Salt Lake City, UT)
Additional Resources:
Download the IMF's Multiple Myeloma Informational Booklets:
Download IMF publications (https://www.myeloma.org/cancer-information-series)
What Is a Clinical Trial? (https://www.myeloma.org/clinical-trials)
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax%20CANOVA_M13-494_NCT03539744_a3.pdf)
clinicaltrials.gov Identifier: NCT03539744 - Phase II Relapsed or Refractory Venetoclax Trial (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-338_NCT02899052_a3.pdf)
clinicaltrials.gov Identifier: NCT02899052 - Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-654_NCT03314181_a3.pdf)
clinicaltrials.gov Identifier: NCT03314181
Workshop Sponsors:
With Support From: Johnson & Johnson, Karyopharm, and Takeda Oncology
(The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)
 |
|
 |
|
|